Q1 2026 · 13F-HR
Jones Hill Capital LPholdings as filed
Filed 2026-05-14 · accession 0002102314-26-000003
$466.5M
Reported value
26
Positions
2026-03-31
Period end
The Brief · Jones Hill Capital LP · Q1 2026
AI · grounded in 13F
Jones Hill Capital LP established a new position in BioMarin Pharmaceutical Inc BMRN valued at $71.7M. The fund also initiated new stakes in Vertex Pharmaceuticals Inc VRTX for $48.5M and Vaxcyte Inc PCVX for $37.5M. Additional new positions include Nuvalent Inc NUVL, Capricor Therapeutics Inc CAPR, and Terns Pharmaceuticals Inc 430.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $71.7M | 15.4% | 1,268,390 | Common | SOLE |
| 92532F100 | VRTX | VERTEX PHARMACEUTICALS INC | $48.5M | 10.4% | 108,603 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $37.5M | 8.03% | 644,831 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $30.8M | 6.61% | 300,830 | Common | SOLE |
| 14070B309 | CAPR | CAPRICOR THERAPEUTICS INC | $27.6M | 5.93% | 909,207 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $27.5M | 5.89% | 521,237 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $25.1M | 5.37% | 1,260,136 | Common | SOLE |
| 00182C103 | ANIP | ANI PHARMACEUTICALS INC | $24.5M | 5.25% | 318,591 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $24.4M | 5.23% | 1,165,557 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $23.2M | 4.98% | 593,040 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $22.2M | 4.76% | 1,598,794 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $19.0M | 4.07% | 25,995 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $13.6M | 2.91% | 1,771,926 | Common | SOLE |
| 92764N102 | VIR | VIR BIOTECHNOLOGY INC | $10.7M | 2.30% | 1,198,213 | Common | SOLE |
| 67080N101 | NUVB | NUVATION BIO INC | $10.2M | 2.19% | 2,383,031 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $6.9M | 1.48% | 140,843 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $6.7M | 1.44% | 513,053 | Common | SOLE |
| 922967104 | MANE | VERADERMICS INC | $6.4M | 1.37% | 100,843 | Common | SOLE |
| 890260839 | TNXP | TONIX PHARMACEUTICALS HLDG C | $6.2M | 1.33% | 452,116 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $4.8M | 1.04% | 100,593 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $4.7M | 1.01% | 374,010 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $4.7M | 1.01% | 167,014 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $4.4M | 0.95% | 370,175 | Common | SOLE |
| 75955J402 | RLMD | RELMADA THERAPEUTICS INC | $2.4M | 0.51% | 342,752 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $1.6M | 0.34% | 301,604 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $1.1M | 0.23% | 45,809 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.